January 2023 Publications
- The impact of BCG dose and revaccination on trained immunity. Debisarun PA, Kilic G, de Bree LCJ, Pennings LJ, van Ingen J, Benn CS, Aaby P, Dijkstra H, Lemmers H, Domínguez-Andrés J, van Crevel R, Netea MG. Clin Immunol. 2023 Jan. doi: 10.1016/j.clim.2022.109208. Epub 2022 Dec 21.
- Finding antigens for TB vaccines: the good, the bad and the useless. Ogongo P, Ernst JD. Nat Med. 2023 Jan. doi: 10.1038/s41591-022-02123-4.
- Indirect effects of cytomegalovirus infection: Implications for vaccine development. Moseley P, Klenerman P, Kadambari S. Rev Med Virol. 2023 Jan. doi: 10.1002/rmv.2405. Epub 2022 Nov 15.
- Intracellular immunoglobulin A (icIgA) in protective immunity and vaccines. Kok TW, Izzo AA, Costabile M. Scand J Immunol. 2023 Jan 3. doi: 10.1111/sji.13253. Online ahead of print.
- Non-Specific Effects of Bacillus Calmette-Guérin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Trunk G, Davidovi M, Bohlius J. Vaccines (Basel). 2023 Jan 4. doi: 10.3390/vaccines11010121.
- The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice. Komine-Aizawa S, Mizuno S, Kawano A, Hayakawa S, Matsuo K, Honda M. Int J Mol Sci. 2023 Jan 4. doi: 10.3390/ijms24020966.
- T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection. Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ. Nat Med. 2023 Jan 5. doi: 10.1038/s41591-022-02110-9.
- Immunoinformatic-Based Multi-Epitope Vaccine Design for Co-Infection of Mycobacterium tuberculosis and SARS-CoV-2. Peng C, Tang F, Wang J, Cheng P, Wang L, Gong W. J Pers Med. 2023 Jan 5. doi: 10.3390/jpm13010116.
- An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis. Larsen SE, Erasmus JH, Reese VA, Pecor T, Archer J, Kandahar A, Hsu F, Nicholes K, Reed SG,Baldwin SL, Coler RN. Vaccines (Basel). 2023 Jan 5. doi: 10.3390/vaccines11010130.
- Characterizing the spectrum of latent Mtb infection in the cynomolgus macaque model: Clinical, immunologic, and PET CT features of evolution. Medrano JM, Maiello P, Rutledge T, Tomko J, Rodgers MA, Fillmore D, Frye LJ, Janssen C, Klein E, Flynn JL, Lin PL. J Infect Dis. 2023 Jan 6. doi: 10.1093/infdis/jiac504.
- Single-cell profiling reveals distinct subsets of CD14+ monocytes drive blood immune signatures of active tuberculosis. Hillman H, Khan N, Singhania A, Dubelko P, Soldevila F, Tippalagama R, DeSilva AD, Gunasena B, Perera J, Scriba TJ, Ontong C, Fisher M, Luabeya A, Taplitz R, Seumois G, Vijayanand P, Hedrick CC, Peters B, Burel JG. Front Immunol. 2023 Jan 11. doi: 10.3389/fimmu.2022.1087010. eCollection 2022.
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments. Valdemar-Aguilar CM, Manisekaran R, Acosta-Torres LS, López-Marín LM. Nanomedicine. 2023 Jan 14. doi: 10.1016/j.nano.2023.102653.
- A Structural View at Vaccine Development against M. tuberculosis. Romano M, Squeglia F, Kramarska E, Barra G, Choi HG, Kim HJ, Ruggiero A, Berisi R. Cells. 2023 Jan 14. doi: 10.3390/cells12020317.
- Towards the development of subunit vaccines against tuberculosis: The key role of adjuvant. Duong VT, Skwarczynski M, Toth I. Tuberculosis (Edinb). 2023 Jan 14. doi: 10.1016/j.tube.2023.102307.
- Impact of SIV infection on mycobacterial lipid-reactive T cell responses in Bacillus Calmette-Guérin (BCG) inoculated macaques. Walker EM, Merino KM, Slisarenko N, Grasperge BF, Mehra S, Roy CJ, Kaushal D, Rout N. Front Immunol. 2023 Jan 16. doi: 10.3389/fimmu.2022.1085786. eCollection 2022.
- Bacillus Calmette-Guérin-induced interleukin-10 inhibits S100A8/A9 production and hinders development of T helper type 1 memory in mice. Wang Y, Su Y, Zheng Y, Yang Y, He L, Qu P, Zhou F, Xu X, Bai X, Chen X, Yuan Y, Liu M, Pan Q. Eur J Immunol. 2023 Jan 21. doi: 10.1002/eji.202250204.
- The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study. Portnoy A, Clark RA, Quaife M, Weerasuriya CK, Mukandavire C, Bakker R, Deol AK, Malhotra S, Gebreselassie N, Zignol M, Sim SY, Hutubessy RCW, Baena IG, Nishikiori N, Jit M, White RG, Menzies NA. PLoS Med. 2023 Jan 24. doi: 10.1371/journal.pmed.1004155.